Status:
RECRUITING
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
Prostate Cancer Foundation
Conditions:
Prostate Cancer
Prostate Cancer Metastatic
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
The overall goal of the study is to improve equitable delivery of pre-Tumor genetic testing (TGT) counseling tool for Black or African American men with metastatic prostate cancer and evaluating the t...
Detailed Description
PRIMARY OBJECTIVES: Stage 1: To evaluate education quality of the intervention in Black or African American men with prostate cancer. Stage 2: To evaluate feasibility of the TGT intervention among B...
Eligibility Criteria
Inclusion
- Stage 1:
- Age 18-years-old or older
- Identifies as Black or African American, by either chart documentation or participant self-report. Mixed-race including Black or African American is included.
- Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
- Able to understand study procedures and to comply with them for the entire length of the study.
- Able to understand a written information sheet and willing to verbally consent.
- Fluent in English (reading, writing, and speaking)
- Stage 2:
- Age 18-years-old or older
- Identifies as Black or African-American, by either chart documentation or participant self-report. Mixed-race including Black or African-American is included.
- Metastatic prostate cancer, by either chart documentation or participant self-report. Pathology report not needed.
- Able to understand study procedures and to comply with them for the entire length of the study.
- Fluent in English (reading, writing, and speaking).
- Anticipated discussion of TGT within 0-90 days of enrollment, per treating oncology provider's discretion. TGT involves use of any cancer genetic sequencing (whether standard-of-care or part of a research protocol) via any one of the following:
- Somatic DNA testing of already-collected tissue.
- Somatic DNA testing of tissue to be collected in the future via biopsy, surgery, or other procedure.
- Blood-based DNA testing to evaluate for circulating tumor DNA.
- Able to understand a written informed consent document and willing to sign it.
Exclusion
- Contraindication to any study-related procedure or assessment in either stage.
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2027
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06171139
Start Date
December 1 2023
End Date
August 31 2027
Last Update
July 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California
San Francisco, California, United States, 94143